

SWITZERLAND TRANSPARENCY REPORT - Angelini Pharma

Date of publication 30/06/2021

	Full name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier OPTIONAL  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	Regazzoni Pietro Federico	Lugano	Switzerland	Strada di Soragno (Sentiero per i Ciapei 8)	-	N/A	N/A	-	-	3.000,00 €	-	3.000,00 €	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						N/A	N/A	-	-	-	-	-
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						N/A	N/A	-	-	-	-	-
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed - <i>Art. 3.02</i>						N/A	N/A	-	-	-	-	-	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	-	-	-	-	-	-	-	-	-	-	-	-	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						-	-	-	-	-	-	-
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						-	-	-	-	-	-	-
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed - <i>Art. 3.02</i>						-	-	-	-	-	-	-	
R&D	<i>AGGREGATE DISCLOSURE</i>												
	Transfers of Value re Research & Development as defined - <i>Article 3.04 and Schedule 1</i>											255.058,00 €	-